Study wrapper · #188
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
Editor's note
A critical narrative review examining peptide and peptide-analogue use as performance enhancers across sport, including several growth-hormone secretagogues, ipamorelin, CJC-1295, sermorelin, and fragments such as Frag 176-191 and KPV. This is a synthesis and commentary paper, not primary data, so its role is to characterise a landscape and its risks rather than to quantify them. The authors' central point aligns with the wider evidence: clinical support for these peptides in sport is limited, because most published studies examine controlled therapeutic dosing, not the supraphysiological, stacked protocols common in bodybuilding. They flagged emerging risk signals, cardiovascular strain, insulin resistance, dyslipidaemia and psychiatric instability, and stressed that an unregulated supply chain compounds danger through mislabelled or contaminated product. True prevalence, especially among recreational and younger users, is unknown. Weight this as risk framing rather than an efficacy assessment: the review concludes these remain experimental substances with poorly defined long-term risks that should be considered high-risk in competitive and recreational settings alike.
Plain-language abstract
This review discussed the growing use of peptides and peptide-like drugs to enhance muscle, fat loss and recovery in sport and bodybuilding. It is an expert commentary summarising the field, not a new experiment. The authors explained that these peptides, including growth-hormone-releasing peptides such as ipamorelin, growth-hormone-releasing hormone analogues such as CJC-1295 and sermorelin, and fragments such as Frag 176-191 and KPV, are promoted as more selective and supposedly safer than anabolic steroids. However, they stressed that the clinical evidence is limited, because most studies tested careful medical doses, not the very high or combined doses often used in bodybuilding. They pointed to emerging risks including strain on the heart, insulin resistance, abnormal blood fats, and mood and psychiatric instability, and warned that a largely unregulated supply means products are often mislabelled or contaminated. They also noted that how widely these peptides are used, especially among ordinary gym-goers and younger people, is simply unknown. The authors concluded that peptides remain experimental substances with poorly understood long-term risks, and that until long-term studies exist, their use in competitive and recreational settings should be regarded as high-risk and ethically problematic.